

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

98205

From: Gibbs, Terra
Sent: Monday, July 07, 2003 9:40 AM
To: STIC-Biotech/ChemLib
Subject: Sequence search request...

RECEIVED

JUL - 7 2003

Could you please do a regular search of SEQ ID NO: 1 of USSN 09/901,910?

RECEIVED
(STIC)

Terra Gibbs
AU 1635
306-3221
Mailbox: 11E12

REGD. AVAILABLE COPY

Edward Hart
Technicai Info. Specialist
STIC/Biotech
CMI 6B02 Tel: 305-9203

Searcher: _____
Phone: _____
Location: *7/17/03*
Date Picked Up: *7/17/03*
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH: /
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: *01*
WWW/Internet: _____
Other (specify): _____

98206

From: Gibbs, Terra
Sent: Monday, July 07, 2003 9:41 AM
To: STIC-Biotech/ChemLib
Subject: Sequence search request...

RECEIVED

JUL - 7 2003

(STIC)

Terra Gibbs
AU 1635
306-3221
Mailbox: 11E12

BEST AVAILABLE COPY

Edward Hart
Technical Info. Specialist
STIC/Biotech
CMI 6B02 Tel: 305-9203

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: 7/18/03
Searcher Prep/Review: 7/18/03
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: 102
WWW/Internet: _____
Other (specify): _____

(FILE 'HOME' ENTERED AT 09:42:16 ON 07 JUL 2003)

FILE 'BIOSIS, MEDLINE, CAPLUS, EMBASE, CANCERLIT' ENTERED AT 09:42:24 ON
07 JUL 2003

L1 588 CYR61
L2 14 CTGF-2
L3 83469 ANGIOGENESIS
L4 240 CAPILLARY SPROUTING
L5 376405 ISCHEMIA
L6 32919 RESTENOSIS
L7 134 L1 AND L3
L8 3 L7 AND L5
L9 18 L7 AND L6
L10 1 DUP REM L8 (2 DUPLICATES REMOVED)
L11 5 DUP REM L9 (13 DUPLICATES REMOVED)
L12 0 L1 AND L4
L13 1 L2 AND L3
L14 9 CONNECTIVE TISSUE GROWTH FACTOR 2
L15 2 L14 AND L3

L10 ANSWER 1 OF 1 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2002457071 MEDLINE
DOCUMENT NUMBER: 22204062 PubMed ID: 12215267
TITLE: Stimulation of angiogenesis by **Cyr61**
gene: a new therapeutic candidate.
AUTHOR: Fataccioli Virginie; Abergel Valerie; Wingertsmann Laure;
Neuville Pascal; Spitz Estelle; Adnot Serge; Calenda
Valerie; Teiger Emmanuel
CORPORATE SOURCE: INSERM U492, Hopital Henri Mondor, 94010 Creteil, France.
SOURCE: HUMAN GENE THERAPY, (2002 Aug 10) 13 (12) 1461-70.
Journal code: 9008950. ISSN: 1043-0342.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20020907
Last Updated on STN: 20030321
Entered Medline: 20030320

AB **Cyr61** is a secreted, cysteine-rich heparin-binding protein that is associated with extracellular matrix and cell surface, and has been demonstrated to be proangiogenic in vitro. In the present study we evaluated the angiogenic effect of human **Cyr61** in an adenoviral context in the rabbit ischemic hindlimb model. For this purpose, three randomized groups of New Zealand White rabbits received intramuscular injections of 5×10^8 infectious units of an adenovirus carrying either the **Cyr61** gene (Ad-**Cyr61**), the vascular endothelial growth factor gene (Ad-VEGF(165)) used as the angiogenic gene of reference, or no transgene (Ad-Null), 10 days after femoral artery excision in one limb. Perfusion of the ischemic limb was evaluated before adenoviral treatment (day 10) and 30 days postinjection (day 40). Angiographic, hemodynamic, and histologic parameters indicated that animals in the Ad-**Cyr61** group had significantly better perfusion than in the Ad-Null group. Interestingly, this improvement exceeded that achieved with Ad-VEGF(165). In conclusion, **Cyr61** gene transfer appears potent in stimulating limb revascularization, thereby promoting great improvement in tissue perfusion in the ischemic limb. These findings indicate that **Cyr61** could be a promising therapeutic candidate for treating severe peripheral ischemic diseases.

L11 ANSWER 1 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1
ACCESSION NUMBER: 2003:67527 BIOSIS
DOCUMENT NUMBER: PREV200300067527
TITLE: Pro-angiogenic activities of **CYR61** (CCN1)
mediated through integrins alphavbeta3 and alpha6beta1 in
human umbilical vein endothelial cells.
AUTHOR(S): Leu, Shr-Jeng; Lam, Stephen C.-T.; Lau, Lester F. (1)
CORPORATE SOURCE: (1) Dept. of Molecular Genetics, College of Medicine,
University of Illinois, 900 S. Ashland Ave., Chicago, IL,
60607-7170, USA: lflau@uic.edu USA
SOURCE: Journal of Biological Chemistry, (November 29 2002) Vol.
277, No. 48, pp. 46248-46255. print.
ISSN: 0021-9258.

DOCUMENT TYPE: Article
LANGUAGE: English

AB **CYR61** (CCN1) is an extracellular matrix-associated protein of the CCN family, which also includes CTGF (CCN2), NOV (CCN3), WISP-1 (CCN4), WISP-2 (CCN5), and WISP-3 (CCN6). Purified **CYR61** induces neovascularization in corneal implants, and **Cyr61**-null mice suffer embryonic death due to vascular defects, thus establishing that **CYR61** is an important regulator of angiogenesis. Aberrant expression of **Cyr61** is associated with breast cancer, wound healing, and vascular diseases such as atherosclerosis and restenosis. In culture, **CYR61** functions through integrin-mediated pathways to promote cell adhesion, migration, and proliferation. Here we show that **CYR61** can also promote cell survival and tubule formation in human umbilical vein endothelial cells. Furthermore, we have dissected the integrin receptor requirements of **CYR61** with respect to its pro-angiogenic activities. Thus, **CYR61**-induced cell adhesion and tubule formation occur through interaction with integrin alpha β 1 in early passage endothelial cells in which integrins have not been activated. By contrast, in endothelial cells in which integrins are activated by phorbol ester or vascular endothelial growth factor, **CYR61**-promoted cell adhesion, migration, survival, growth factor-induced mitogenesis, and endothelial tubule formation are all mediated through integrin alphavbeta3. These findings indicate that **CYR61** is an activation-dependent ligand of integrin alphavbeta3 and an activation-independent ligand of integrin alpha β 1 and that these integrins differentially mediate the pro-angiogenic activities of **CYR61**. These findings help to define the mechanisms by which **CYR61** acts as an angiogenic regulator, provide a molecular interpretation for the loss of vascular integrity and increased apoptosis of vascular cells in **Cyr61**-null mice, and underscore the importance of **CYR61** in the development and homeostasis of the vascular system.

L11 ANSWER 2 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
ACCESSION NUMBER: 2003:961 BIOSIS
DOCUMENT NUMBER: PREV20030000961
TITLE: **CYR61** (CCN1) is essential for placental development and vascular integrity.
AUTHOR(S): Mo, Fan-E.; Muntean, Andrew G.; Chen, Chih-Chiun; Stolz, Donna B.; Watkins, Simon C.; Lau, Lester F. (1)
CORPORATE SOURCE: (1) Department of Molecular Genetics, University of Illinois at Chicago, 900 South Ashland Ave., Chicago, IL, 60607-7170, USA: LFLau@uic.edu USA
SOURCE: Molecular and Cellular Biology, (December 2002, 2002) Vol. 22, No. 24, pp. 8709-8720. print.
ISSN: 0270-7306.

DOCUMENT TYPE: Article
LANGUAGE: English

AB **CYR61** (CCN1) is a member of the CCN family of secreted matrixcellular proteins that includes connective tissue growth factor (CCN2), NOV (CCN3), WISP-1 (CCN4), WISP-2 (CCN5), and WISP-3 (CCN6). First

identified as the product of a growth factor-inducible immediate-early gene, **CYR61** is an extracellular matrix-associated angiogenic inducer that functions as a ligand of integrin receptors to promote cell adhesion, migration, and proliferation. Aberrant expression of **Cyr61** is associated with breast cancer, wound healing, and vascular diseases such as atherosclerosis and **restenosis**. To understand the functions of **CYR61** during development, we have disrupted the **Cyr61** gene in mice. We show here that **Cyr61**-null mice suffer embryonic death: apprx30% succumbed to a failure in chorioallantoic fusion, and the remainder perished due to placental vascular insufficiency and compromised vessel integrity. These findings establish **CYR61** as a novel and essential regulator of vascular development. **CYR61** deficiency results in a specific defect in vessel bifurcation (nonsprouting angiogenesis) at the chorioallantoic junction, leading to an undervascularization of the placenta without affecting differentiation of the labyrinthine syncytiotrophoblasts. This unique phenotype is correlated with impaired Vegf-C expression in the allantoic mesoderm, suggesting that **CYR61**-regulated expression of Vegf-C plays a role in vessel bifurcation. The genetic and molecular basis of vessel bifurcation is presently unknown, and these findings provide new insight into this aspect of angiogenesis.

L11 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 3
ACCESSION NUMBER: 2002:242004 BIOSIS
DOCUMENT NUMBER: PREV200200242004

TITLE: The angiogenic factor cysteine-rich 61 (**CYR61**, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha β 1 and cell surface heparan sulfate proteoglycans.
AUTHOR(S): Grzeszkiewicz, Tatiana M.; Lindner, Volkhard; Chen, Ningyu; Lam, Stephen C.-T.; Lau, Lester F. (1)
CORPORATE SOURCE: (1) Department of Molecular Genetics, College of Medicine, University of Illinois at Chicago, 900 South Ashland Avenue, Chicago, IL, 60607-7170: lflau@uic.edu USA
SOURCE: Endocrinology, (April, 2002) Vol. 143, No. 4, pp. 1441-1450. <http://endo.endojournals.org/>. print.
ISSN: 0013-7227.

DOCUMENT TYPE: Article
LANGUAGE: English

AB Cysteine-rich 61 (**CYR61**, CCN1) is a heparin-binding, extracellular, matrix-associated protein of the cysteine-rich 61/nephroblastoma family, which also includes connective tissue growth factor, nephroblastoma overexpressed, Wnt-induced secreted protein-1 (WISP-1), WISP-2, and WISP-3. **CYR61** induces angiogenesis in vivo and supports cell adhesion, promotes cell migration, and enhances growth factor-stimulated mitogenesis in fibroblasts and endothelial cells. Although the expression of **CYR61** has been observed in arterial walls, its function in vascular smooth muscle cells (VSMCs) has not been examined to date. Here we show that purified **CYR61** supports VSMC adhesion in a dose-dependent, saturable manner through integrin alpha β 1 with an absolute requirement of cell surface heparan sulfate proteoglycans. In addition, **CYR61** induces VSMC chemotaxis, but not chemokinesis, through integrin alpha β 1 and heparan sulfate proteoglycans. Heparin-binding defective **CYR61** mutants are unable to support VSMC adhesion but can still induce chemotaxis at a reduced level. Following balloon angioplasty in rat carotid artery, **CYR61** protein level is elevated in the media and neointima of the injured vessel by d 4 post angioplasty, peaks from d 7 to 14, and remains high for at least 28 d. These data demonstrate the activities of **CYR61** in VSMCs, identify the receptors that mediate its functions, and show that **CYR61** is synthesized in arterial smooth muscle walls during proliferative **restenosis**. Together, these results implicate **CYR61** as a novel factor that modulates the responses

of VSMCs' to vascular injury.

L11 ANSWER 4 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 4
ACCESSION NUMBER: 2000:501632 BIOSIS
DOCUMENT NUMBER: PREV200000501753
TITLE: Characterization of differential gene expression in monkey
arterial neointima following balloon catheter injury.
AUTHOR(S): Wu, Kai-Jin; Yee, Ann; Zhu, Nian Ling; Gordon, Erlinda M.;
Hall, Frederick L. (1)
CORPORATE SOURCE: (1) Gene Therapy Laboratories, USC School of Medicine, 1975
Zonal Avenue, KAM300, Los Angeles, CA, 90089-9025 USA
SOURCE: International Journal of Molecular Medicine, (October,
2000) Vol. 6, No. 4, pp. 433-440. print.
ISSN: 1107-3756.

DOCUMENT TYPE: Article
LANGUAGE: English

SUMMARY LANGUAGE: English

AB Vaso-occlusive sequelae following percutaneous transluminal coronary angioplasty (PTCA), including smooth muscle cell migration, proliferation, and attendant extracellular matrix production, often results in **restenosis** of the treated artery. To further understand the molecular mechanisms governing progressive intimal hyperplasia, we performed a molecular screen using differential display PCR on total RNA prepared from injured and normal carotid arterial segments to identify a subset of differentially expressed genes at t=7 days post-balloon catheter injury in a non-human primate. DNA sequence analysis of selected differentially expressed RNA by this procedure using 240 combinations of random primer pairs yielded 41 distinct cDNA sequences: 22 of which have significant sequence homology to previously identified metazoan genes, 15 GEMS (genes expressed in monkey neointima), and 4 GSMS (genes suppressed in monkey neointima) that have little homology to reported sequences. Among the up-regulated homologues include i) secreted growth regulatory factors, ii) membrane receptors, iii) transcription factors, iv) cell adhesion molecules, and v) extracellular matrix proteins; some of which have not been previously linked to vascular **restenosis**. In particular, **Cyr61**, a known **angiogenesis** inducer, was found to be highly expressed in the neointima lesion of the balloon-injured monkey artery. This finding provides the first links of **Cyr61** to the pathogenesis of vascular **restenosis**, and identifies a novel locus for potential therapeutic intervention. These studies identified a number of known and unknown genes, whose up- or down-regulated expression during the proliferative phase of vascular **restenosis** makes them potential targets for therapeutic intervention.

L11 ANSWER 5 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2003:238273 BIOSIS
DOCUMENT NUMBER: PREV200300238273
TITLE: **Cyr61** (CCN1) is essential for placental development and vascular integrity.
AUTHOR(S): Mo, F.-E. (1); Muntean, A. G. (1); Stolz, D. B.; Watkins, S. C.; Lau, L. F. (1)
CORPORATE SOURCE: (1) Department of Molecular Genetics, University of Illinois at Chicago, 900 South Ashland Avenue, Chicago, IL, 60607-7170, USA USA
SOURCE: Molecular Pathology, (April 2003, 2003) Vol. 56, No. 2, pp. 70. print.
Meeting Info.: Second International Workshop on the CCN Family of Genes Saint Malo, France October 20-23, 2002
ISSN: 1366-8714.
DOCUMENT TYPE: Conference
LANGUAGE: English

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:42819 CAPLUS
DOCUMENT NUMBER: 138:83829
TITLE: Connective tissue growth factor-2
INVENTOR(S): Li, Haodong; Adams, Mark; Calenda, Valerie;
Fataccioli, Virginie
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S.
Ser. No. 348,815.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003012768	A1	20030116	US 2001-901910	20010711
WO 9601896	A1	19960125	WO 1994-US7736	19940712
W: AT, AU, CA, CN, JP, KR, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1217067	A2	20020626	EP 2002-398	19940712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
ES 2180585	T3	20030216	ES 1994-925090	19940712
US 5945300	A	19990831	US 1995-459101	19950602
US 6534630	B1	20030318	US 1999-348815	19990708
PRIORITY APPLN. INFO.:			WO 1994-US7736	W 19940712
			US 1995-459101	A3 19950602
			US 1999-348815	A2 19990708
			US 2000-217402P	P 20000711
			US 2001-291642P	P 20010518
			EP 1994-925090	A3 19940712

AB The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:42819 CAPLUS
 DOCUMENT NUMBER: 138:83829
 TITLE: Connective tissue growth
 factor-2
 INVENTOR(S): Li, Haodong; Adams, Mark; Calenda, Valerie;
 Fataccioli, Virginie
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S.
 Ser. No. 348,815.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003012768	A1	20030116	US 2001-901910	20010711
WO 9601896	A1	19960125	WO 1994-US7736	19940712
W: AT, AU, CA, CN, JP, KR, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1217067	A2	20020626	EP 2002-398	19940712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
ES 2180585	T3	20030216	ES 1994-925090	19940712
US 5945300	A	19990831	US 1995-459101	19950602
US 6534630	B1	20030318	US 1999-348815	19990708
PRIORITY APPLN. INFO.:			WO 1994-US7736	W 19940712
			US 1995-459101	A3 19950602
			US 1999-348815	A2 19990708
			US 2000-217402P	P 20000711
			US 2001-291642P	P 20010518
			EP 1994-925090	A3 19940712

AB The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:51492 CAPLUS
 DOCUMENT NUMBER: 136:113173
 TITLE: Connective tissue growth
 factor-2 polypeptide and encoding
 DNA for use in stimulating angiogenesis and
 in treating ischemic disease states
 INVENTOR(S): Li, Haodong; Adams, Mark D.; Calenda, Valerie;
 Fataccioli, Virginie
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Transgene S.A.
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002004480 A2 20020117 WO 2001-US21799 20010711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1217067 A2 20020626 EP 2002-398 19940712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
ES 2180585 T3 20030216 ES 1994-925090 19940712
AU 2001076868 A5 20020121 AU 2001-76868 20010711
PRIORITY APPLN. INFO.: US 2000-217402P P 20000711
US 2001-291642P P 20010518
EP 1994-925090 A3 19940712
WO 2001-US21799 W 20010711

AB The present invention relates to a human CTGH-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed. Administration of the polypeptide of the present invention in combination with pharmaceutically acceptable carriers are also claimed.

WEST Search History

DATE: Monday, July 07, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L10	L3 and L4	2	L10
L9	L2 and L4	4	L9
L8	L1 and L4	26	L8
L7	restenosis	14248	L7
L6	ischemia	19907	L6
L5	capillary sprouting	13	L5
L4	angiogenesis	13038	L4
L3	connective tissue growth factor 2	14	L3
L2	ctgf-2	16	L2
L1	cyr61	72	L1

END OF SEARCH HISTORY

WEST**Search Results - Record(s) 1 through 10 of 26 returned.**

1. Document ID: US 20030113816 A1

L8: Entry 1 of 26

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113816

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030113816 A1

TITLE: Methods of assaying connective tissue growth factor

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weitz, Stephen L.	Oakland	CA	US	
Usinger, William R.	Lafayatte	CA	US	

US-CL-CURRENT: 435/7.9; 435/7.92

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC
Drawn	Delete	Image									

2. Document ID: US 20030109438 A1

L8: Entry 2 of 26

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109438

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030109438 A1

TITLE: Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baker, Kevin P.	Darnestown	MD	US	
Ferrara, Napoleone	San Francisco	CA	US	
Gerber, Hanspeter	San Francisco	CA	US	
Gerritsen, Mary E.	San Mateo	CA	US	
Goddard, Audrey	San Francisco	CA	US	
Godowski, Paul J.	Hillsborough	CA	US	
Gurney, Austin L.	Belmont	CA	US	
Hillan, Kenneth J.	San Francisco	CA	US	
Marsters, Scot A.	San Carlos	CA	US	
Pan, James	Belmont	CA	US	
Stephan, Jean-Philippe F.	Millbrae	CA	US	
Watanabe, Colin K.	Moraga	CA	US	
Williams, P. Mickey	Half Moon Bay	CA	US	
Wood, William I.	Hillsborough	CA	US	
Ye, Weilan	Foster City	CA	US	

US-CL-CURRENT: 514/12, 435/183, 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

3. Document ID: US 20030087259 A1

L8: Entry 3 of 26

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087259

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087259 A1

TITLE: Methods and compositions for regulating bone and cartilage formation

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Clancy, Brian M.	Ashland	MA	US	
Pittman, Debra D.	Windham	NH	US	

US-CL-CURRENT: 435/6; 702/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

4. Document ID: US 20030073637 A1

L8: Entry 4 of 26

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073637

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030073637 A1

TITLE: Method for stimulating connective tissue growth or wound healing

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uutela, Marko	University of Helsinki		FI	
Eriksson, Ulf	Stockholm		SE	
Alitalo, Kari	University of Helsinki		FI	

US-CL-CURRENT: 514/12; 435/320.1, 435/455, 514/44

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KIMC](#)
[Draw](#) [Desc](#) [Image](#)

5. Document ID: US 20030068678 A1

L8: Entry 5 of 26

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068678

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068678 A1

TITLE: WISP polypeptides and nucleic acids encoding same

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Levine, Arnold J.	Princeton	NJ	US	
Pennica, Diane	Burlingame	CA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.5

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KIMC](#)
[Draw](#) [Desc](#) [Image](#)

6. Document ID: US 20030055511 A1

L8: Entry 6 of 26

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055511

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030055511 A1

TITLE: Shaped particle comprised of bone material and method of making the particle

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schryver, Jeffrey E.	Cordova	TN	US	
Cooper, Michael B.	Memphis	TN	US	
Kinnane, Keith M.	Bartlett	TN	US	
Long, Marc	Memphis	TN	US	
Allen, Trevor	York	TN	GB	
Margerrison, Ed	York	CA	GB	
Morgan, Robert	Bartlett		US	
Bearcroft, Julie A.	York		US	
Harrison, Andrew	Sunnyvale		GB	
Kaiser, William B.			US	

US-CL-CURRENT: 623/23.5; 623/16.11, 623/23.63, 623/919

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KMC
 Draw Desc | Image

7. Document ID: US 20030027151 A1

L8: Entry 7 of 26

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027151

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030027151 A1

TITLE: Regulator gene and system useful for the diagnosis and therapy of osteoporosis

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Warman, Matthew L.	Shaker Heights	OH	US	
Gong, Yaoqin	Jinan	MA	CN	
Olsen, Bjorn R.	Milton		US	
Rawadi, Georges	Paris		FR	
Roman-Roman, Sergio	Paris		FR	

US-CL-CURRENT: 435/6; 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KMC
 Draw Desc | Image

8. Document ID: US 20030012768 A1

L8: Entry 8 of 26

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012768

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030012768 A1

TITLE: Connective tissue growth factor-2

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Haodong	Gaithersburg	MD	US	
Adams, Mark	North Potomac	MD	US	
Calenda, Valerie	Strasbourg		FR	
Fataccioli, Virginie	Thiais		FR	

US-CL-CURRENT: 424/93.2; 435/456, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draft	Desc	Image								

9. Document ID: US 20020193302 A1

L8: Entry 9 of 26

File: PGPB

Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020193302

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020193302 A1

TITLE: Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ezban, Mirella	Copenhagen O		DK	
Petersen, Lars Christian	Horsholm		DK	
Siegbahn, Agneta	Uppsala		DK	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draft	Desc	Image								

10. Document ID: US 20020164719 A1

L8: Entry 10 of 26

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164719

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164719 A1

TITLE: Targeting pharmaceutical agents to injured tissues

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hall, Frederick L.	Glendale	CA	US	
Gordon, Erlinda M.	Glendale	CA	US	
Starnes, Vaughn A.	Pasadena	CA	US	
Anderson, W. French	San Marino	CA	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/69.5, 530/351, 530/384, 530/391.1

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KOMC](#)
[Draw Desc](#) [Image](#)

[Generate Collection](#)

[Print](#)

Term	Documents
(1 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	26
(L1 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	26

[Display Format:](#)

[Previous Page](#) [Next Page](#)

WEST**Search Results - Record(s) 11 through 20 of 26 returned.**

11. Document ID: US 20020150986 A1

L8: Entry 11 of 26

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150986

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150986 A1

TITLE: Extracellular matrix signalling molecules

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lau, Lester F.	Chicago	IL	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 514/12, 530/388.26, 536/23.2

<input type="button" value="Full"/>	<input type="button" value="Title"/>	<input type="button" value="Citation"/>	<input type="button" value="Front"/>	<input type="button" value="Review"/>	<input type="button" value="Classification"/>	<input type="button" value="Date"/>	<input type="button" value="Reference"/>	<input type="button" value="Sequences"/>	<input type="button" value="Attachments"/>	<input type="button" value="KWMC"/>
<input type="button" value="Draw Desc"/>	<input type="button" value="Image"/>									

12. Document ID: US 20020132978 A1

L8: Entry 12 of 26

File: PGPB

Sep 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020132978

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020132978 A1

TITLE: VEGF-modulated genes and methods employing them

PUBLICATION-DATE: September 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerber, Hans-Peter	San Francisco	CA	US	
Rastelli, Luca	Guilford	CT	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.1, 536/23.5

<input type="button" value="Full"/>	<input type="button" value="Title"/>	<input type="button" value="Citation"/>	<input type="button" value="Front"/>	<input type="button" value="Review"/>	<input type="button" value="Classification"/>	<input type="button" value="Date"/>	<input type="button" value="Reference"/>	<input type="button" value="Sequences"/>	<input type="button" value="Attachments"/>	<input type="button" value="KWMC"/>
<input type="button" value="Draw Desc"/>	<input type="button" value="Image"/>									

13. Document ID: US 20020106746 A1

L8: Entry 13 of 26

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106746
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106746 A1

TITLE: Anti-inflammatory vectors

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rooke, Ronald	Illkirch		FR	

US-CL-CURRENT: 435/91.33, 424/199.1, 424/204.1, 424/233.1, 424/93.21, 435/235.1,
435/320.1, 435/456, 435/91.41, 530/388.7, 536/23.72

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) KMC
[Draw Desc](#) [Image](#)

14. Document ID: US 20020055174 A1

L8: Entry 14 of 26

File: PGPB

May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055174
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020055174 A1

TITLE: Complex for transferring an anionic substance of interest into a cell

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rittner, Karola	Strasbourg		FR	
Jacobs, Eric	Stotheim		FR	

US-CL-CURRENT: 435/463, 530/350

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) KMC
[Draw Desc](#) [Image](#)

15. Document ID: US 20020052308 A1

L8: Entry 15 of 26

File: PGPB

May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052308
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020052308 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 514/1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1,
530/350, 536/23.1

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC
 Draw Desc Image

16. Document ID: US 20020049304 A1

L8: Entry 16 of 26

File: PGPB

Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020049304

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020049304 A1

TITLE: Human CCN-like growth factor

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hastings, Gregg A.	Germantown	MD	US	
Adams, Mark D.	North Potomac	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.4, 536/23.5

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC
 Draw Desc Image

17. Document ID: US 6492129 B1

L8: Entry 17 of 26

File: USPT

Dec 10, 2002

US-PAT-NO: 6492129

DOCUMENT-IDENTIFIER: US 6492129 B1

TITLE: Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grotendorst, Gary R.	Miami	FL		

US-CL-CURRENT: 435/7.21; 424/198.1, 435/252.3, 435/254.11, 435/320.1, 435/325,
435/69.1, 435/69.4, 435/7.1, 530/350, 530/351, 530/399

Full Title Citation Front Review Classification Date Reference Sequences Attachments KMC
 Draw Desc Image

18. Document ID: US 6413735 B1

L8: Entry 18 of 26

File: USPT

Jul 2, 2002

US-PAT-NO: 6413735

DOCUMENT-IDENTIFIER: US 6413735 B1

TITLE: Method of screening for a modulator of angiogenesis

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lau; Lester F.	Chicago	IL		

US-CL-CURRENT: 435/29; 424/9.1, 424/9.2, 435/174, 435/4, 435/7.1, 435/7.2, 435/7.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

 19. Document ID: US 6387663 B1

L8: Entry 19 of 26

File: USPT

May 14, 2002

US-PAT-NO: 6387663

DOCUMENT-IDENTIFIER: US 6387663 B1

TITLE: Targeting pharmaceutical agents to injured tissues

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hall; Frederick L.	Glendale	CA		
Gordon; Erlinda M.	Glendale	CA		
Starnes; Vaughn A.	Pasadena	CA		
Anderson; W. French	San Marino	CA		

US-CL-CURRENT: 435/69.7; 424/1.69, 424/520, 424/9.4, 424/93.7, 435/174, 435/180,
435/252.3, 435/366, 435/395, 435/4, 435/69.1, 530/350, 530/402

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

 20. Document ID: US 6387657 B1

L8: Entry 20 of 26

File: USPT

May 14, 2002

US-PAT-NO: 6387657

DOCUMENT-IDENTIFIER: US 6387657 B1

** See image for Certificate of Correction **

TITLE: WISP polypeptides and nucleic acids encoding same

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Botstein; David A.	Belmont	CA		
Cohen; Robert L.	San Mateo	CA		
Goddard; Audrey D.	San Francisco	CA		
Gurney; Austin L.	Belmont	CA		
Hillan; Kenneth J.	San Francisco	CA		
Lawrence; David A.	San Francisco	CA		
Levine; Arnold J.	New York	NY		
Pennica; Diane	Burlingame	CA		
Roy; Margaret Ann	San Francisco	CA		
Wood; William I.	Hillsborough	CA		

US-CL-CURRENT: 435/69.1, 435/243, 435/252.33, 435/255.1, 435/320.1, 435/325,
435/358, 435/69.4, 536/23.1, 536/23.5, 536/23.51

Term	Documents
(1 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	26
(L1 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	26

Display Format:

Previous Page Next Page

WEST

Search Results - Record(s) 21 through 26 of 26 returned.

21. Document ID: US 6331396 B1

L8: Entry 21 of 26

File: USPT

Dec 18, 2001

US-PAT-NO: 6331396

DOCUMENT-IDENTIFIER: US 6331396 B1

TITLE: Arrays for identifying agents which mimic or inhibit the activity of interferons

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Silverman; Robert H.	Beachwood	OH		
Williams; Bryan R. G.	Cleveland	OH		
Der; Sandy	Cleveland	OH		

US-CL-CURRENT: 435/6; 435/287.2, 536/23.1, 536/23.52, 536/24.3, 536/24.31

<input type="button" value="Full"/>	<input type="button" value="Title"/>	<input type="button" value="Citation"/>	<input type="button" value="Front"/>	<input type="button" value="Review"/>	<input type="button" value="Classification"/>	<input type="button" value="Date"/>	<input type="button" value="Reference"/>	<input type="button" value="Sequences"/>	<input type="button" value="Attachments"/>	<input type="button" value="KINIC"/>
<input type="button" value="Draw Desc"/>	<input type="button" value="Image"/>									

22. Document ID: US 5780263 A

L8: Entry 22 of 26

File: USPT

Jul 14, 1998

US-PAT-NO: 5780263

DOCUMENT-IDENTIFIER: US 5780263 A

TITLE: Human CCN-like growth factor

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hastings; Gregg A.	Germantown	MD		
Adams; Mark D.	North Potomac	MD		

US-CL-CURRENT: 435/59.1; 435/252.3, 435/320.1, 435/325, 536/23.5

<input type="button" value="Full"/>	<input type="button" value="Title"/>	<input type="button" value="Citation"/>	<input type="button" value="Front"/>	<input type="button" value="Review"/>	<input type="button" value="Classification"/>	<input type="button" value="Date"/>	<input type="button" value="Reference"/>	<input type="button" value="Sequences"/>	<input type="button" value="Attachments"/>	<input type="button" value="KINIC"/>
<input type="button" value="Draw Desc"/>	<input type="button" value="Image"/>									

23. Document ID: WO 9733995 A2

L8: Entry 23 of 26

File: EPAB

Sep 18, 1997

PUB-N0: WO009733995A2

DOCUMENT-IDENTIFIER: WO 9733995 A2

TITLE: EXTRACELLULAR MATRIX SIGNALLING MOLECULES

PUBN-DATE: September 18, 1997

INVENTOR-INFORMATION:

NAME	COUNTRY
LAU, LESTER F	US

INT-CL (IPC): C12 N 15/12; C07 K 14/475; C07 K 16/22; C12 N 5/10; A61 K 38/18; C12 N 5/08; A61 K 48/00; G01 N 33/68

EUR-CL (EPC): C07K014/475

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw	Desc	Image								

 24. Document ID: KR 2002089336 A WO 200155210 A2 AU 200134721 A EP 1254174 A2

L8: Entry 24 of 26

File: DWPI

Nov 29, 2002

DERWENT-ACC-NO: 2001-465561

DERWENT-WEEK: 200322

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Novel human cysteine-rich protein 61 (Cyr61) fragment useful in methods for screening for modulators of cell adhesion, fibroblast cell proliferation, angiogenesis and cell migration

INVENTOR: GREENSPAN, J A; LAU, L F ; YEUNG, C

PRIORITY-DATA: 2000US-238705P (October 6, 2000), 2000US-0495448 (January 31, 2000), 2000US-204364P (May 15, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
KR 2002089336 A	November 29, 2002		000	C07K014/475
WO 200155210 A2	August 2, 2001	E	186	C07K014/475
AU 200134721 A	August 7, 2001		000	C07K014/475
EP 1254174 A2	November 6, 2002	E	000	C07K014/475

INT-CL (IPC): A01 K 67/027; A61 P 9/00; A61 P 19/04; A61 P 21/00; C07 K 14/475; C12 N 15/63; C12 Q 1/00; G01 N 33/68

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw	Desc	Image								

 25. Document ID: CZ 200200040 A3 WO 200105353 A2 AU 200058075 A BR 200012408 A NO 200200130 A EP 1200116 A2 KR 2002025194 A US 20020193302 A1 ZA 200110560 A

L8: Entry 25 of 26

File: DWPI

Apr 16, 2003

DERWENT-ACC-NO: 2001-147255

DERWENT-WEEK: 200336

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Use of a tissue factor agonist or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis

INVENTOR: EZBAN, M; PETERSEN, L C ; SIEGBAHN, A

PRIORITY-DATA: 1999DK-0001117 (August 12, 1999), 1999DK-0001023 (July 14, 1999), 1999US-148300P (August 11, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CZ 200200040 A3	April 16, 2003		000	A61K038/36
WO 200105353 A2	January 25, 2001	E	051	A61K000/00
AU 200058075 A	February 5, 2001		000	A61K000/00
BR 200012408 A	March 12, 2002		000	A61K038/36
NO 200200130 A	March 13, 2002		000	A61K000/00
EP 1200116 A2	May 2, 2002	E	000	A61K038/36
KR 2002025194 A	April 3, 2002		000	A61K038/36
US 20020193302 A1	December 19, 2002		000	A61K038/37
ZA 200110560 A	December 24, 2002		067	A61K000/00

INT-CL (IPC): A61 K 0/00; A61 K 38/17; A61 K 38/36; A61 K 38/37; A61 P 17/02; A61 P 35/00

[Full](#) |
 [Title](#) |
 [Citation](#) |
 [Front](#) |
 [Review](#) |
 [Classification](#) |
 [Date](#) |
 [Reference](#) |
 [Sequences](#) |
 [Attachments](#) |
 [KIND](#) |
 [Drawn Desc](#) |
 [Image](#)

26. Document ID: US 20020150986 A1 WO 9733995 A2 AU 9723296 A EP 888452 A2
 CN 1222193 A JP 2000506732 W AU 733382 B AU 200135049 A US 6413735 B1

L8: Entry 26 of 26

File: DWPI

Oct 17, 2002

DERWENT-ACC-NO: 1997-470875

DERWENT-WEEK: 200270

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Isolated and purified cysteine rich protein 61, Cyr61 - useful to modulate e.g. haemostasis, induce wound healing, promote organ regeneration etc

INVENTOR: LAU, L F

PRIORITY-DATA: 1996US-013958P (March 15, 1996), 2001AU-0035049 (April 6, 2001), 1999US-0142569 (April 2, 1999), 2002US-0053753 (January 22, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020150986 A1	October 17, 2002		000	A61K038/17
WO 9733995 A2	September 18, 1997	E	132	C12N015/12
AU 9723296 A	October 1, 1997		000	C12N015/12
EP 888452 A2	January 7, 1999	E	000	C12N015/12
CN 1222193 A	July 7, 1999		000	C12N015/12
JP 2000506732 W	June 6, 2000		144	C12N015/09
AU 733382 B	May 10, 2001		000	C12N015/12
AU 200135049 A	October 18, 2001		000	C07K014/475
US 6413735 B1	July 2, 2002		000	C12Q001/02

INT-CL (IPC): A61 K 35/76; A61 K 38/00; A61 K 38/17; A61 K 38/18; A61 K 48/00; A61 K 49/00; A61 P 9/00; A61 P 11/00; A61 P 17/02; A61 P 19/00; A61 P 35/00; A61 P 43/00; C07 H 21/04; C07 K 1/14; C07 K 14/475; C07 K 14/52; C07 K 16/22; C07 K 16/40; C12 N 5/06; C12 N 5/08; C12 N 5/10; C12 N 9/00; C12 N 15/09; C12 N 15/12; C12 P 21/02; C12 P 21/08; C12 Q 1/00; C12 Q 1/02; C12 Q 1/68; G01 N 33/15; G01 N 33/53; G01 N 33/567; G01 N 33/577; G01 N 33/68

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

KWIC

[Draw Desc](#) | [Image](#)

[Generate Collection](#)

[Print](#)

Term	Documents
(1 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	26
(L1 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	26

[Display Format:](#) [Change Format](#)

[Previous Page](#) [Next Page](#)

WEST**Search Results - Record(s) 1 through 4 of 4 returned.**

1. Document ID: US 20030125247 A1

L9: Entry 1 of 4

File: PGPB

Jul 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030125247
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030125247 A1

TITLE: Albumin fusion proteins

PUBLICATION-DATE: July 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Haseltine, William A.	Washington	DC	US	

US-CL-CURRENT: 514/12; 530/363

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KWD

2. Document ID: US 20030027751 A1

L9: Entry 2 of 4

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027751
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027751 A1

TITLE: VEGF fusion proteins

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kovesdi, Imre	Rockville	MD	US	
Kessler, Paul D.	Frederick	MD	US	

US-CL-CURRENT: 514/12; 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Drawn Desc	Image								

KWD

3. Document ID: US 20030012768 A1

L9: Entry 3 of 4

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012768

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030012768 A1

TITLE: Connective tissue growth factor-2

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Haodong	Gaithersburg	MD	US	
Adams, Mark	North Potomac	MD	US	
Calenda, Valerie	Strasbourg		FR	
Fataccioli, Virginie	Thiais		FR	

US-CL-CURRENT: 424/93.2; 435/456, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KINIC
Draw Desc	Image									

 4. Document ID: WO 200204480 A2 AU 200176868 A

L9: Entry 4 of 4

File: DWPI

Jan 17, 2002

DERWENT-ACC-NO: 2002-171698

DERWENT-WEEK: 200308

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Stimulating angiogenesis in a mammal preferably human having ischemia or restenosis or is treated for limb revascularization, by administering connective tissue growth factor-2 polypeptide or polynucleotide

INVENTOR: ADAMS, M D; CALENDA, V ; FATACCIOLI, V ; LI, H

PRIORITY-DATA: 2001US-291642P (May 18, 2001), 2000US-217402P (July 11, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200204480 A2	January 17, 2002	E	131	C07K000/00
AU 200176868 A	January 21, 2002		000	C07K000/00

INT-CL (IPC): C07 K 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KINIC
Draw Desc	Image									

Term	Documents
(2 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	4
(L2 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	4

Display Format:

[Previous Page](#) [Next Page](#)

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 2 of 2 returned.

 1. Document ID: US 20030012768 A1

L10: Entry 1 of 2

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030012768

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030012768 A1

TITLE: Connective tissue growth factor-2

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Li, Haodong	Gaithersburg	MD	US	
Adams, Mark	North Potomac	MD	US	
Calenda, Valerie	Strasbourg		FR	
Fataccioli, Virginie	Thiais		FR	

US-CL-CURRENT: 424/93.2; 435/456, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMD
Draw Desc	Image									

 2. Document ID: WO 200204480 A2 AU 200176868 A

L10: Entry 2 of 2

File: DWPI

Jan 17, 2002

DERWENT-ACC-NO: 2002-171698

DERWENT-WEEK: 200308

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Stimulating angiogenesis in a mammal preferably human having ischemia or restenosis or is treated for limb revascularization, by administering connective tissue growth factor-2 polypeptide or polynucleotide

INVENTOR: ADAMS, M D; CALENDA, V; FATACCIOLI, V; LI, H

PRIORITY-DATA: 2001US-291642P (May 18, 2001), 2000US-217402P (July 11, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200204480 A2	January 17, 2002	E	131	C07K000/00
AU 200176868 A	January 21, 2002		000	C07K000/00

INT-CL (IPC): C07 K 0/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#)
[Draw Desc](#) | [Image](#)

[Generate Collection](#)

[Print](#)

Term	Documents
(3 AND 4).USPT,PGPB,JPAB,EPAB,DWPI.	2
(L3 AND L4).USPT,PGPB,JPAB,EPAB,DWPI.	2

[Display Format:](#) [Change Format](#)

[Previous Page](#) [Next Page](#)

End of Result Set**Generate Collection**

L3: Entry 1 of 1

File: USPT

Aug 31, 1999

US-PAT-NO: 5945300

DOCUMENT-IDENTIFIER: US 5945300 A

** See image for Certificate of Correction **

TITLE: Connective tissue growth factor-2

DATE-ISSUED: August 31, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Haodong	Gaithersburg	MD	20878	
Adams; Mark D.	North Potomac	MD	20878	

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/455, 435/471, 435/69.4,
530/399, 536/23.5, 536/23.51

CLAIMS:

What is claimed is:

1. An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of:
 - (a) a nucleic acid sequence encoding the polypeptide shown as amino acid residues -24 to 351 of SEQ ID NO:2;
 - (b) a nucleic acid sequence encoding the polypeptide shown as amino acid residues -23 to 351 of SEQ ID NO:2;
 - (c) a nucleic acid sequence encoding the polypeptide shown as amino acid residues 1 to 351 of SEQ ID NO:2;
 - (d) a nucleic acid sequence encoding a fragment of the polypeptide shown as amino acid residues 1 to 351 of SEQ ID NO:2, wherein said polypeptide fragment retains the ability to stimulate cellular proliferation; and
 - (e) a nucleic acid sequence complementary to the nucleic acid sequence of (a), (b), (c), or (d).
2. The isolated polynucleotide of claim 1 wherein said nucleic acid sequence is (a).
3. The isolated polynucleotide of claim 1 wherein said nucleic acid sequence is (b).
4. The isolated polynucleotide of claim 1 wherein said nucleic acid sequence is (c).
5. The isolated polynucleotide of claim 1 comprising the nucleic acid sequence shown as nucleotides 1 to 1125 in SEQ ID NO: 1.
6. The isolated polynucleotide of claim 1 wherein said polynucleotide is DNA and further wherein said nucleic acid sequence is (a), (b), (c), (d) or (e).
7. A vector comprising the DNA of claim 6.

8. A recombinant host cell comprising the DNA of claim 6.
9. A polynucleotide comprising the DNA of claim 6 linked to a heterologous regulatory sequence which controls gene expression.
10. A process for producing a polypeptide comprising expressing from the host cell of claim 8 the encoded polypeptide and recovering said polypeptide.
11. The isolated polynucleotide of claim 1 consisting of a nucleic acid sequence selected from the group consisting of:
 - (a) a nucleic acid sequence encoding the polypeptide shown as amino acid residues -24 to 351 of SEQ ID NO:2;
 - (b) a nucleic acid sequence encoding the polypeptide shown as amino acid residues -23 to 351 of SEQ ID NO:2;
 - (c) a nucleic acid sequence encoding the polypeptide shown as amino acid residues 1 to 351 of SEQ ID NO:2;
 - (d) a nucleic acid sequence encoding a fragment of the polypeptide shown as amino acid residues 1 to 351 of SEQ ID NO:2, wherein said polypeptide fragment retains the ability to stimulate cellular proliferation; and
 - (e) a nucleic acid sequence complementary to the nucleic acid sequence of (a), (b), (c), or (d).
12. The isolated polynucleotide of claim 11 wherein the nucleic acid sequence is (a), (b), (c), or (d).
13. The isolated polynucleotide of claim 12 fused to a heterologous polynucleotide.
14. The isolated polynucleotide of claim 13 wherein said polynucleotide is DNA.
15. A vector comprising the DNA of claim 14.
16. A recombinant host cell comprising the DNA of claim 14.
17. The isolated DNA of claim 14 linked to a regulatory sequence which controls gene expression.
18. A process for producing a polypeptide comprising expressing from the host cell of claim 16 the encoded polypeptide and recovering said polypeptide.
19. An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of:
 - (a) a nucleic acid sequence encoding the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
 - (b) a nucleic acid sequence encoding the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
 - (c) a nucleic acid sequence encoding a fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804, wherein said polypeptide fragment retains the ability to stimulate cellular proliferation; and
 - (d) a nucleic acid sequence complementary to the nucleic acid sequence of (a), (b), or (c).
20. The isolated polynucleotide of claim 19 wherein said nucleic acid sequence is (a).

21. The isolated polynucleotide of claim 19 wherein said nucleic acid sequence is (b).
22. The isolated polynucleotide of claim 19 wherein said nucleic acid sequence encodes an amino acid sequence comprising amino acid residues 1 to 351 of SEQ ID NO:2.
23. The isolated polynucleotide of claim 19 wherein said nucleic acid sequence is (d).
24. The isolated polynucleotide of claim 19 wherein said polynucleotide is DNA and further wherein said nucleic acid sequence is (a), (b), or (c).
25. A vector comprising the DNA of claim 24.
26. A recombinant host cell comprising the DNA of claim 24.
27. A polynucleotide comprising the DNA of claim 24 linked to a heterologous regulatory sequence which controls gene expression.
28. A process for producing a polypeptide comprising expressing from the host cell of claim 26 the encoded polypeptide and recovering said polypeptide.
29. The isolated polynucleotide of claim 19 consisting of a nucleic acid sequence selected from the group consisting of:
 - (a) a nucleic acid sequence encoding the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
 - (b) a nucleic acid sequence encoding the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
 - (c) a nucleic acid sequence encoding a fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804, wherein said polypeptide fragment retains the ability to stimulate cellular proliferation; and
 - (d) a nucleic acid sequence complementary to the nucleic acid sequence of (a), (b), or (c).
30. The isolated polynucleotide of claim 29 wherein the nucleic acid sequence is (a), (b), or (c).
31. The isolated polynucleotide of claim 30 fused to a heterologous polynucleotide.
32. The isolated polynucleotide of claim 30 wherein said polynucleotide is DNA.
33. A vector comprising the DNA of claim 32.
34. A recombinant host cell comprising the DNA of claim 32.
35. The isolated DNA of claim 32 linked to a regulatory sequence which controls gene expression.
36. A process for producing a polypeptide comprising expressing from the host cell of claim 34 the encoded polypeptide and recovering said polypeptide.
37. The isolated polypeptide produced by the process of claim 10.
38. The isolated polypeptide produced by the process of claim 18.
39. The isolated polypeptide produced by the process of claim 28.
40. The isolated polypeptide produced by the process of claim 36.

41. An isolated polypeptide comprising a polypeptide selected from the group consisting of:

- (a) a polypeptide consisting of amino acid residues -24 to 351 of SEQ ID NO:2;
- (b) a polypeptide consisting of amino acid residues -23 to 351 of SEQ ID NO:2;
- (c) a polypeptide consisting of amino acid residues 1 to 351 of SEQ ID NO:2;
- (d) a fragment of the polypeptide consisting of amino acid residues 1 to 351 of SEQ ID NO:2, wherein said fragment retains the ability to stimulate cellular proliferation.

42. The isolated polypeptide of claim 41 wherein said polypeptide comprises the polypeptide of (a).

43. The isolated polypeptide of claim 41 wherein said polypeptide comprises the polypeptide of (b).

44. The isolated polypeptide of claim 41 wherein said polypeptide comprises the polypeptide of (c).

45. The isolated polypeptide of claim 41 wherein said polypeptide comprises the polypeptide of (d).

46. The isolated polypeptide of claim 41 consisting of a polypeptide selected from the group consisting of:

- (a) a polypeptide consisting of amino acid residues -24 to 351 of SEQ ID NO:2;
- (b) a polypeptide consisting of amino acid residues -23 to 351 of SEQ ID NO:2;
- (c) a polypeptide consisting of amino acid residues 1 to 351 of SEQ ID NO:2;
- (d) a fragment of the polypeptide consisting of amino acid residues 1 to 351 of SEQ ID NO:2, wherein said fragment retains the ability to stimulate cellular proliferation.

47. The isolated polypeptide of claim 41 wherein said polypeptide is fused to a heterologous polypeptide.

48. An isolated polypeptide comprising a polypeptide selected from the group consisting of:

- (a) a polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
- (b) a mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;
- (c) a fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804, wherein said fragment retains the ability to stimulate cellular proliferation.

49. The isolated polypeptide of claim 48 wherein said polypeptide comprises the polypeptide of (a).

50. The isolated polypeptide of claim 48 wherein said polypeptide comprises the polypeptide of (b).

51. The isolated polypeptide of claim 48 wherein said polypeptide comprises the polypeptide of (c).

52. The isolated polypeptide of claim 48 consisting of a polypeptide selected from the group consisting of:

(a) a polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;

(b) a mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804;

(c) a fragment of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 75804, wherein said fragment retains the ability to stimulate cellular proliferation.

53. The isolated polypeptide of claim 52, wherein said polypeptide is fused to a heterologous polypeptide.